Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05631574 · ClinicalTrials.gov registry record · Phase 1
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1 study, sponsored by Biomea Fusion.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT05631574 is a Phase 1 study that was terminated before completion, run by Biomea Fusion. The registered enrollment target is 13 participants.
The verdict
NCT05631574, a Phase 1 study, was terminated before completion, sponsored by Biomea Fusion.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).
Interventions
- DRUG BMF-219
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-01-12 |
| Est. Completion | 2025-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05631574
The ClinicalTrials.gov registry entry for NCT05631574 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biomea Fusion, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMF-219 is the first listed.
NCT05631574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05631574 about?
NCT05631574 is a clinical study titled "Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer". A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).
What is the current status of trial NCT05631574?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2023-01-12. Estimated completion is 2025-01-15.
What interventions are being tested in trial NCT05631574?
The interventions under investigation include: BMF-219 (DRUG).
Who is sponsoring clinical trial NCT05631574?
This trial is sponsored by Biomea Fusion, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.